The first deadline for REACH registration has passed and registration data for the first set of substances are now public. According to ECHA, 4,599 
Introduction
On December 30, 2006, the Regulation on Registration, Evaluation, Authorization and restriction of Chemicals (REACH, 2006) was published in the Official Journal of the European Union. The driving force for the creation of this regulation was the awareness that thousands of chemicals are circulating and used by european citizens despite an enormous lack of information about their (eco)toxicological characteristics. the possible risk of chemicals is a major concern for european citizens: when asked how likely they feel, personally, that environmental chemicals damage their health, eurobarometers from 2005 and 2010 stably indicated that 18% considered this "very likely" and 43% "fairly likely" (Eurobarometer 73.5 from 06/2010 and 64.1 from 09-10/2005) .
This Regulation therefore requires that all chemicals that are marketed and/or manufactured in the european Union in quantities above one ton per year must be fully characterized as to the impact they may have on both human health and the environment. This process requires that a long list of endpoints be addressed, mainly through in vivo experiments. The list of tests that must be considered in the dossiers depends on the tonnage band of the manufactured/marketed chemicals and is more demanding for higher quantities, with steps at 1, 10, 100 and 1000 t/a. Above 10 t/a the registration dossier must also contain a Chemical Safety Report (CSR) that is the result of an extensive Chemical Safety Assessment (CSA).
The REACH regulation sets three deadlines to make old chemicals, i.e., those registered as existing chemicals before the deadline of the Dangerous Substances Directive in 1981, comply with the new requirements. Old chemicals are now defined as "phase-in substances" and correspond to substances found in the EINECS database. Those deadlines are: 1. November 30, 2010 -All substances imported/manufactured in quantities above 1000 t/a -All substances imported/manufactured in quantities above 1 t/a that are classified as CMRs category 1 or 2 according to Directive 67/548
(Globally Harmonized System of Classification and Labelling of Chemicals). The GHS is a United Nations system to identify hazardous chemicals and to inform users about these hazards through standard pictograms and phrases on the packaging labels, as well as through safety data sheets (SDS).
In addition to the differences in the hazard statements that now begin with "H" instead of the old "R" phrases, a very important revolution is in place: submitters are now fully responsible for the classification and assessment of the chemical substances that they either manufacture or import into the EU. CLP still contains in its Annex I a full list of chemicals with mandatory harmonized classification, but it is explicitly required that whenever a new hazard is known, it must be immediately communicated to downstream users and consumers. In this sense, the list of Annex I can be considered as only a starting point for classification.
After the first deadline of November 30, 2010, ECHA published a database containing data from all submitted dossiers, excluding what was claimed as confidential. On May 6, 2011, this database contained 4,071 entries relating to 3,242 registered substances. Recently, ECHA published a series of reports providing many details about the registration process (ECHA Reports, 2011a-c). These reports are informative but remain very general, as they do not go in depth into the type of data that are presented by submitters. ECHA is planning an extensive review of only 5% of those dossiers that do not contain testing proposals.
In the present paper, data from 400 submitted dossiers were analyzed to check for compliance with REACH Regulations and published guidelines. The dossiers were randomly selected among full phase-in registered substances, therefore excluding all ELINCS substances and intermediates. For the reasons given above, the study focuses only on reproductive and developmental toxicity.
Reproductive and developmental toxicity: REACH -CLP requirements
Studies on reproductive and developmental toxicity are required from Annex VIII onwards, i.e. for all substances marketed or manufactured in quantities above 10 t/a. Moving from Annex VIII through x, the required information for reproductive and developmental toxicity becomes more extensive, as explained in Table 1 , which gives the relevant text from REACH. It should be noted that the original requirement (Column 2 of 8.7.2 and identical 8.7.3), about considering a 2 nd species, was later deleted: "The study shall be initially performed on one species. A decision on the need to perform a study at this tonnage level or the next on a second species should be based on the outcome of the first test and all other relevant data."
The ECHA guidance about all specific endpoints (ECHA, 2008) explains how to adapt the test requirements (adaptation of Column 2 of REACH Regulation and application of the provisions of Annex XI). In particular, it defines OECD TG 421 and 422 as screening tests demanded by Annex VIII and OECD shall be always adopted, i.e. any official OECD or EU Test Guideline (TG) can be applied as soon as it is published. The use of such methods becomes compulsory when they replace in vivo tests on vertebrate animals. 2. All existing data on a substance must be gathered and used before performing new tests. The concept of Weight of Evidence is introduced: when more than two independent studies are available and provide the same result, this result can be accepted despite the lack of full reliability of the study, the lack of GLP compliance, or because insufficient data for a full assessment are provided or the data are derived from non-validated methods. Existing data to be considered include historical human data and epidemiological studies. 3. Article 30 of REACH asks for sharing of all data. All potential registrants for a given substance must manage the registration process jointly, forming a SIEF (Substance Information Exchange Forum). This is done to avoid repeating tests in general. In particular, data sharing is mandatory for in vivo tests. This provision is valid also for companies that are not themselves interested in the registration of that substance but that own the data. The concept of "one substance, one registration" is introduced. 4. New tests can be waived when considered either not necessary or not applicable. The waiving option is suggested, for example, when complete lack of exposure is demonstrated or when an endpoint of greater concern has already been confirmed. 5. Similar substances do not require double tests. The data from a similar substance can be used (read-across) or new tests can be performed on one representative substance of a group of similar substances (grouping). Applicability of those options is not straightforward, and it requires solid scientific argumentation, as they must not compromise human and environmental health due to misleading results. With this aim, a team of experts in different sectors delivered an extensive document: "Guidance on information requirements and chemical safety assessment: endpoint specific requirements," which is now publicly available on the ECHA website (ECHA, 2008) to provide instruction regarding how to apply adaptations for information requirements for each endpoint. Other relevant guidelines are available for download from the ECHA website 1 .
It was clear from the beginning, however, that many new in vivo tests would be required, as most of the substances circulating in the european Union lack very basic information about their (eco) toxicological properties (Hartung, 2010) . In particular, reproductive toxicity and developmental toxicity created the highest concern, as these tests are very demanding in terms of animals and costs, and few data were available when REACH was approved (Rovida and Hartung, 2009; Hartung and Rovida, 2009a) .
A new Regulation that complements REACH was published in 2008 and entered into force in 2009. Addressing classification, labelling and packaging of substances and mixtures (CLP, 2008) , this Regulation aligns previous EU legislation on classification, labelling and packaging of chemicals with the GHS -the substance is known to be a germ cell mutagen and appropriate risk management on structurally related substances, measures are implemented, or from (Q)SAR estimates or from in vitro -relevant human exposure can be excluded in accordance with Annex XI section 3, or methods that the substance may be -a pre-natal developmental toxicity study (Annex IX, 8.7 .2) or a two-generation a developmental toxicant reproductive toxicity study (Annex IX, Section 8.7.3) is available. If a substance is known to have an adverse effect on fertility, meeting the criteria for classification as Repr Cat 1 or 2: R60, and the available data are adequate to support a robust risk assessment, then no further testing for fertility will be necessary. However, testing for developmental toxicity must be considered.
If a substance is known to cause developmental toxicity, meeting the criteria for classification as Repr Cat 1 or 2: R61, and the available data are adequate to support a robust risk assessment, then no further testing for developmental toxicity will be necessary. However, testing for effects on fertility must be considered.
In cases where there are serious concerns about the potential for adverse effects on fertility or development, either a pre-natal developmental toxicity study (Annex IX, Section 8.7.2) or a two-generation reproductive toxicity study (Annex IX, Section 8.7.3) may be proposed by the registrant instead of the screening study.
Annex IX
8.7. Reproductive toxicity 8.7. The studies do not need to be conducted if:
-the substance is known to be a genotoxic carcinogen and appropriate risk management measures are implemented, or -the substance is known to be a germ cell mutagen and appropriate risk management measures are implemented, or -the substance is of low toxicological activity (no evidence of toxicity seen in any of the tests available), it can be proven from toxicokinetic data that no systemic absorption occurs via relevant routes of exposure (e.g. plasma/blood concentrations below detection limit using a sensitive method and absence of the substance and of metabolites of the substance in urine, bile or exhaled air) and there is no or no significant human exposure.
If a substance is known to have an adverse effect on fertility, meeting the criteria for classification as Repr Cat 1 or 2: R60, and the available data are adequate to support a robust risk assessment, then no further testing for fertility will be necessary. However, testing for developmental toxicity must be considered.
8.7.2. Pre-natal developmental toxicity 8.7.2. The study shall be initially performed on one species. A decision on the need study, one species, most appropriate to perform a study at this tonnage level or the next on a second species should be based route of administration, having regard to on the outcome of the first test and all other relevant available data. the likely route of human exposure (B.31 of the Commission Regulation on test methods as specified in Article 13(3) or OECD 414).
tal neurotoxicity) are not considered as standard methods for REACH requirements, even though existing data are accepted. Repeated-dose toxicity studies may also provide indications for considering the need to investigate developmental neurotoxicity endpoints. Interestingly, the ECHA guidance still refers to the second species for OeCD 414 but no longer for 416, and thus, at this point, is more demanding than REACH: "At this tonnage level, progression beyond Stage 1 and 2 will trigger a prenataldevelopmental toxicity study (EU B.31, OECD TG 414) and a two-generation reproductive toxicity study (EU B.35, OECD TG 416) in the most relevant species as a standard data requirement. The need for a developmental toxicity study (EU B.31, OECD TG 414) -the substance is known to be a genotoxic carcinogen and appropriate risk management measures are implemented, or -the substance is known to be a germ cell mutagen and appropriate risk management measures are implemented, or -the substance is of low toxicological activity (no evidence of toxicity seen in any of the tests available), it can be proven from toxicokinetic data that no systemic absorption occurs via relevant routes of exposure (e.g. plasma/blood concentrations below detection limit using a sensitive method and absence of the substance and of metabolites of the substance in urine, bile or exhaled air) and there is no or no significant human exposure.
If a substance is known to cause developmental toxicity, meeting the criteria for classification as Repr Cat 1 or 2: R61, and the available data are adequate to support a robust risk assessment, then no further testing for developmental toxicity will be necessary. However, testing for effects on fertility must be considered. An important difference between the two regulations is relevant to this paper: REACH clearly distinguishes between reproductive toxicity and developmental toxicity, while CLP keeps reproductive toxicity and prenatal developmental toxicity together and splits the toxicity via lactation into a separate section. The result is that the risk for toxicity via lactation is not very well addressed in REACH registration dossiers, as it has no specific fields in the IUCLID software, but the endpoint is included in the developmental toxicity section.
Finally, it must be noted that special rules are adopted in certain circumstances. For example, isolated intermediates that are either used on site or transported must also be registered with exactly the same deadlines. The dossier is much lighter, however, and no information on reproductive/developmental toxicity is required.
ECHA report about "The use of Alternatives to Testing on Animals for the REACH Regulation"
According to the provision of Article 117(3) of REACH, every three years ECHA is requested to publish a report on the status of implementation and use of non-animal test methods and testing strategies. The first report was published on the ECHA website on June 30, 2011 (ECHA Report, 2011c : "The Use of Alternatives to Testing on Animals for the REACH Regulation." The report, however, reports not only on uses of alternatives to testing but also includes read-across and data sharing, even though
In vivo tests required in Annexes VII and VIII are immediately mandatory, while in vivo tests described in Annexes IX and X must first undergo a public consultation as a result of a testing proposal. However, when substances require longer tests, corresponding shorter tests shall be waived (ECHA Press Release, 2009 ). This concept is further underscored in an ECHA Fact Sheet that was specific for both repeated dose and reproductive toxicity (ECHA REACH Fact Sheet, 2009 substances marketed above 1 t/a and classified as carcinogenic, mutagenic, and toxic for reproduction (CMR). Excluding these groups of substances of highest concern from the calculation may mean excluding the most problematic substances with regard to testing requirements. The text just states that the percentages presented in table 3 are unchanged when non-phase-in substances and substances registered in the tonnage band above 100 t/a are included. The tables in this report are about submitted studies only. Therefore, information on how many dossiers have empty fields is completely missing, and there is no way to analyze whether something should have been done but has not, i.e. whether a registration dossier lacks important studies. The ECHA report states once more that screening tests for assessing reproductive toxicity are not acceptable for the evaluation of substances marketed at a higher tonnage band. It is clearly stated that OeCD tG 414 is required for substances marketed above 100 t/a, and OeCD tG 416 is required for substances marketed above 1000 t/a.
Interestingly, these tables do not contain information about in vitro approaches. In the whole report, the in vitro approach is considered only for mutagenicity, skin and eye irritation. This confirms that no in vitro methods are applied in the testing strategies (Rovida, 2010) for more complex endpoints. From this report it is evident that complex animal tests have been waived through read-across and exploitation of existing data but not by employing alternative test methods or computational methods. Also, very few testing proposals for definitive tests on reproductive toxicity have been submitted, as many of the registrants chose to run screening for reproductive toxicity only, despite the fact that this is explicitly considered insufficient.
Materials and methods
Data used in the present report were collected on the ECHA website, in the special section dedicated to the full database of submitted dossiers 2 ; after the update of May 6, 2011, this they are not alternative methods, thereby raising the number of "alternative methods use" dramatically.
this report was published simultaneously with a general report about the first years of implementation of REACH and CLP (ECHA Report, 2011b) . Both documents are very important to give an understanding of what has happened in recent years. According to this report, by the first deadline of November 30, ECHA had received submissions for 4,599 substances, including phase-in and non-phase-in substances but excluding intermediates. In this report, all dossiers are further analyzed to identify the number of new testing proposals, the type of experimental studies that are considered, and all other opportunities taken to avoid new tests. Only submitted tests performed after 2009 are considered as performed for REACH purposes. These criteria are applied to analyze the entries related to all dossiers, i.e. all studies that have been inserted in a dossier. Regarding toxicity to reproduction and developmental toxicity (paragraph 3.2.7 of this report) the analyses is on 3,533 and 4,217 entries, respectively that are all entries submitted (Tab. 3). In fact, requisite number one of REACH is gathering all information related to that substance and this may lead to several entries for one endpoint for one substance. The result is that a dossier often contains more than one entry per endpoint. Thus the relevance of this table is questionable, as it gives a higher weight to studied substances with multiple entries -some chemicals have up to 10 entries of existing data -compared to non-studied substances, which have just one entry for a waiving option or a new testing proposal ( Fig.  1 with some further explanation in the section about Materials and Methods). The report does not explicitly state how many substances are included, stating only that it addresses phase-in substances registered in the tonnage band >1000 t/a. According to the same report, 1,504 phase-in substances are registered at a tonnage band above 1000 t/a. Considering only substances that were registered at the highest tonnage band is also questionable, as the 2010 deadline included not only all substances marketed above 1000 t/a but also all substances marketed above 100 t/a and classified as toxic for the environment, as well as all that was recorded for that selected substance. These possibilities are: -Data lacking (default value) -Inconclusive -Conclusive, but not sufficient for classification -H360, H361 (Reproductive Toxicity) -H362 (Toxicity via Lactation) Afterward, the area on toxicological information was analyzed.
In some cases the field about toxicity to reproduction did not exist, and in those cases it was flagged as "void" (Fig. 1) . In many cases, more than one study was inserted in both fields, and therefore some rules were applied to set priorities. The entry was considered as "waived" when this was the only proposal, i.e. no other studies were presented. When not void and not waived, all entries were analyzed, and the key study selected for further assessment. When more than one key study was found, the most relevant (when in doubt, the most recent one) was selected. In most cases, both these criteria were met by the key study. However, all entries were checked, even if they were not included in our file. Data inserted in the section: "other studies" were also considered to aid our assessment, even though not transposed to our Excel file. This decision was taken as few studies were presented and most of them were not homogeneous. When a study was selected, the following parameters were considered: -Reference type: Publication / Study Report -Purpose Flag: Key study / supporting study / weight of evidence / disregarded study; in addition: Waiving / Study planned / (Q)SAR / in vitro -Reliability: 1-4, according to the Klimisch score system -Year when the study was performed (sometimes it was not distinguishable from the date of the publication or report issue) -test Guideline, as reported by the submitter -Species -Test material: Yes, same as submitted dossier; No, different. The "No" flag triggers the "Read across selection" for the study -Substance that was used as read across, if that was the case -Final Result, expressed as LOAEL (Lower Adverse Effect level) the same scheme was applied for both reproductive and developmental toxicity.
Besides the selected study, all other entries were checked for the presence of second species, in vitro tests, or (Q)SAR approaches. If one of these possibilities was used, a second study was considered. All data were stored in an Excel worksheet for further assessment. Details on substance identities and final results are not reported.
Results and discussion

General considerations on the approach taken
even though the set of 400 substances can be considered as representative, the present approach has some limitations. The selection was totally random, and the only control was to discard substances that were registered as intermediates only. No other controls were in place, so there is no certainty whether, for database contained 4,071 records. A new update was released recently, and the number of records increased to 4,413 (October 19, 2011) . However, the present work does not consider the subsequent updates and is entirely based on the May 6 version.
Many records in this database are related to the same substances, as they have the same EC numbers. By removing all multiple entries, the database was reduced to 3,685 records. According to ECHA, 4,599 substances have been registered so far, but it is not clear how to explain the difference of 914 fewer substances in the database. The database should contain data from all publishable dossiers, i.e. dossiers where authorization for publication has been formally received from the submitter. However, there is no further explanation about the procedure that is in place to go from the assignment of a registration number to the publication of the corresponding dossier in the database. We have to assume that the database is representative of the whole set of registered substances, i.e., 4,599.
For the present assessment, we picked randomly 400 different substances from the database from the whole range of eC numbers, only excluding 4xx-numbers. The 4xx-numbers are assigned to ELINCS substances that are already considered as registered according to REACH. Dossiers for those substances are not standard and therefore not representative of a full registration dossier. Another category that was excluded is that of intermediates, either isolated on site or transported. Dossiers for intermediates do not require data about reproductive/developmental toxicity. Information about the type of the submitted dossier was retrieved from an Excel File named "list_substanc-es_phasein.xls", which was downloaded from the sector of the ECHA website 3 in the area titled "List of registered substances." This file lists the publishable substances with a flag indicating whether the registration was for a commercial chemical or for an intermediate. The Excel file version used in the present work was dated May 6, 2011. The latest update was released on September 27, 2011 and contains 3,861 substances.
the assessment started by transferring all database records into an Excel worksheet and sorting them by EC number. Afterward, about one out of every 10 entries was selected and checked in the list_substances_phasein.xls file to determine whether it was related to an intermediate or to a full dossier. In the case of an intermediate, it was discarded and another one selected. The next step was to insert the EC number into the database query on the webpage. When multiple records were returned, they were all evaluated to remove partially filled dossiers. Only the most complete one was selected and the corresponding dossier opened. The following data were checked: → Classification and labelling → GHS → Reproductive Toxicity → Reproductive Toxicity → Toxicity via lactation → Toxicological information → Toxicity to reproduction → Toxicity to reproduction → Developmental toxicity → Toxicity to reproduction: other studies (hardly ever present) In case a dossier included different impurity profiles, classification of the purest was selected. Classification only had one entry REACH, ELINCS substances are considered registered. A full REACH compliant dossier is required for ELINCS substances for an update in tonnage band and/or in case a new company needs the right to market that substance. As the reason for the presence of an ELINCS substance in the database is not known, all ELINCS substances were disregarded.
Substances registered as intermediates only were excluded, as no data on reproductive toxicity is required for these. In the example, there are enough representatives for CMRs or other classes of chemicals. Moreover, in the public database there is no information about the tonnage band of the dossiers; some early registrations for later deadlines or non-phase-in substances might have been included.
In our analysis, all ELINCS substances (chemicals registered under the Dangerous Substances Directive) had been removed before the set of 400 chemicals was picked. According to Conclusions are that more than 90% of the studies on reproductive toxicity are performed on rats, with the mouse as the second most common species of choice. In the area of developmental toxicity, about 80% of studies are on rats, followed by an equal number of studies performed on mice and rabbits, as well as some hamster use. There were only three studies on dogs and one on monkeys, all very old studies. Sheep were used in only one study on reproductive toxicity for a UVCB substance, with no support from additional studies. The same substance has no entry for developmental toxicity, but at least the "inconclusive" flag was selected for CLP. Beyond the anecdotal, it is clear that most of the submitters accepted the results from one species without seeking confirmation of negative results in a second species, as is still suggested in the ECHA guidance for OECD 414 (see above) but deleted from the REACH text. However, the opposite also was found: some studies were on a second species, or such a repeat was suggested when the first one was positive in order to either confirm, or more likely to challenge, the positive outcome or to better understand the mechanism of action. Very often, a positive result is explained as a general toxicity of the substance to the mother and not as a consequence of a real activity of the substance as a reproductive/developmental toxicant. Thus, quite often a positive result is associated with a negative classification of the substance.
The field for epidemiological data was filled in some dossiers, even though it was not considered in the present assessment. In general, however, it appears that epidemiological data are reported but not used for risk characterization, giving a claim of insufficient statistical meaning. We feel that these data are precious and should at least trigger a more in-depth analysis if any alert is raised.
Each analyzed dossier would need further comments. Even though many of them are clearly prepared with care by a team of experts, others lack basic common sense, suggesting that the dossier was prepared in a very superficial manner, despite the REACH request for a detailed chemical risk assessment. Just one example: a substance is classified as "conclusive, but insufficient for classification" for reproductive toxicity. No other classification is assigned, so now that substance can be distributed among consumers with no limitations. In the field for reproductive toxicity, there is the input of a screening test based on OeCD tG 421, where the outcome is clearly positive with a reported NOAEL of 60 mg/kg. In addition, there is another study inserted in the field of "Specific investigations" demonstrating an activity of that substance as an endocrine disruptor. According to the submitter, the result from the latter study is "questionable" and no further investigation is proposed.
Another important gap represents developmental neurotoxicity and endocrine disruption that probably represent a concern for some chemicals. However, those endpoints are not explicitly requested by REACH and therefore they are generally not taken into consideration during the preparation of a dossier. In only few cases, those endpoints were mentioned as "other studies", but hardly ever included in the final assessment.
A particularly sore point is that in vitro tests are completely absent. An in vitro test was reported in just three cases and in each case it was performed before 2006 and was already present ECHA general report (ECHA Report, 2011b) , however, it is stated that 86% of the substances presented as intermediates appear not to contain sufficient information to demonstrate that the criteria for intermediates are fulfilled. This goes beyond the aim of this paper, however.
Even with no access to the full Chemical Safety Report (CSR), some general considerations regarding the quality of the submitted dossiers are possible. It was evident that there are different interpretations of what IUCLID requires as input. For example, the first recorded input for all dossiers was whether the study was retrieved from a publication or archived as a Company Internal Report. In many dossiers, public studies that are not published in a peer-reviewed journal are regarded as internal reports. In this way, the US National Toxicology Program (NTP) studies, for example, were inserted as either internal or public, making it impossible to use this field for further assessments.
Before entering the study details, some other general information is requested, such as the purpose flag of the study (key study / supporting study / weight of evidence / disregarded study). Obviously, a key study is crucial in the final CSR, and this was always selected when available.
For reliability of the study, the submitter could select among the four different Klimisch scores (Klimisch et al., 1997) , i.e.: 1. Reliable without restriction 2. Reliable with restrictions 3. Not reliable 4. Not assignable The submitter defines the score, and it seems there is a variety of interpretation. Almost all studies performed in the last four to five years were assigned the Klimisch score 1. However, in the area of reproductive toxicity, 10 studies performed before 1990 were also given a Klimisch score of 1. Even though the GLP concept was implemented in 1978, it was not generally applied before the early 1990s, so a Klimisch score of 1 is questionable. This is also the impression with regard to the quality of the data found in the dossiers. Notably, there are also two studies ranked Klimisch 2 and dated 1956 and 1952, respectively. The 1952 study is the only one presented for the assessment of reproductive toxicity of the given substance. Apparently the outcome of that study is positive, but the substance is still classified as "conclusive, but not sufficient for classification." Similar conclusions come from the analysis of the section about reproductive toxicity with 29 studies rated Klimisch 1 and performed before 1990.
In this database almost no justification is given when the waiving option is selected, even though this must be present in the corresponding CSR. In some cases it was possible to guess that the waiving option derives from the existence of a Risk Assessment Report (RAR), which represents the official position of the European Commission about a specific chemical or group of chemicals. In the RAR, all studies that led to a decision are presented and commented upon. In those cases the waiving decision is backed by available data. However, the selection of the waiving option in these cases is not correct, and it was not done in the same way for all substances where an RAR is available.
Other general considerations about the submitted dossiers are necessary for animal species selections. Each set of studies per substance was checked for the presence of different species.
it was possible to identify all substances that have been registered as intermediates. It was also possible to note that the database contains many double entries, i.e. that more than one dossier was presented for a given chemical. This contradicts the REACH principle "one substance, one registration." ECHA is not sure how this could happen (ECHA Report, 2011b). One substance was found with eight entries and others have seven entries. Probably, each dossier is dedicated to a different use of the substance, but these would need to be combined for the exposure assessment. For the scope of the present assessment, when multiple entries were present, only the one containing the most studies on reproductive toxicity was considered. The full database contains dossiers for 3,685 different substances, as further characterized in Table 4 .
Another important difference between the two files refers to the presence in the database of some substances that are missing in the Excel file. Most of these substances are characterized by an EC number of 7xx, having only five representatives in the Excel file and 195 in the database (Tab. 4). In the database, there are also 118 entries with no name, and most of them lack a CAS number as well. Characterization seems very difficult or even impossible.
What is evident from this analysis is that many registered substances are not unique chemical entities, but rather a combination of many chemicals, defined as UVCB (Unknown and Variable Composition, Biological materials). The ECHA Report (2011b) states that this opportunity has been quite extensively applied. In order to try to quantify this contribution, the number of UVCB substances in the ECHA database comes to 1,284 out of 3,484 phase-in substances, i.e. 37% of the total. The counting was manual, considering all substances as UVCB where the name did not identify a unique chemical entity. A comparison was made with the current situation in the USA: In fact, all US marketed substances, governed by the Toxic Substance Control Act (TSCA), are listed in a file 6 on the EPA website. In the TSCA list there are 16,550 UVCBs substances out of 66,664 entries, representing 25% of the total. In this case, counting was easier, as there is a specific flag for identifying UVCBs in the list. The conclusion is that the EU database contains 12% more UVCBs than expected from the US data over all tonnage bands. It also appears that sometimes substances have been grouped into one dossier. As the full CSR is not accessible, the number of substances that are grouped into one registration is not known. However, this situation is confirmed in ECHA report 2011b:
"Companies should ensure that the number of registrations to be made is not artificially reduced by expanding the definition of a substance or merging SIEFs for substances which have entirely different compositions."
The companies' approach is fully understandable. In fact, beyond the number of tests that are required per substance, preparation of each dossier is very demanding. It was estimated that up to 10,000 entries are required for one dossier in IUClID (ECHA Report, 2011b). Copy and paste options in IUCLID are in the public literature, demonstrating that no new alternative tests were done for REACH purposes. This confirms our previous analysis (Rovida, 2010) . This is really a missed opportunity, despite the validated embryotoxicity and endocrine disruptor tests and the success of the ReProTect project 4 , an Integrated Project funded by the european Commission that ended with the development of many interesting new tests for reproductive and developmental toxicity. This field definitely deserves more attention in the future, and future submitters should consider in vitro alternatives before doing or planning any in vivo methods, as also suggested by REACH in several Articles.
General considerations on the database published on the ECHA website
On the ECHA website, there is a section dedicated to registered substances 5 . This area includes the link to enter into the full database of submitted dossiers. This database contained 4,071 records after the update of May 6, 2011 and 4,413 records after the October 19, 2011 update. Accepting a disclaimer is mandatory for entering the database: "Information on Registered
Substances at http://apps.echa.europa.eu/registered/registeredsub.aspx comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with REACH. ECHA cannot guarantee the correctness of the information in the database and the REACH Regulation does not permit it to make modifications to the data provided by registrants."
Before inserting a new dossier into this database, ECHA removes some fields that are considered either confidential or not useful for public dissemination. Above all, these include the full CSR text file, which contains the full assessment of the substance and explains all criteria applied, such as justification for read-across and waiving. Another important field that is missing is the endpoint summary, which has a window for "justification for classification." Due to this, it is very difficult to understand why a specific classification is presented despite the discordant results in the studies that are also present in the dossier.
On the same web page, there is also a table that clearly explains the organization of the EC numbers (Tab. 4). The full explanation was already given (Rovida and Hartung, 2009 ). The only new aspect is the presence of the 7xx numbers that are related to substances that were not pre-registered.
Furthermore, in the area of registered substances on the ECHA website, it is possible to download an Excel file that contains additional information, such as the type of dossier that has been presented for each substance, i.e. whether it is a full dossier or a dossier for isolated intermediates. This Excel file list includes all substances defined as "Publishable Phase-in Substances." It is not clear which substances are not included in this list, nor how many.
By comparing the records of the database and the substances that are listed in the Excel file (of the same date of update) why some dossiers simply do not have that information is difficult to explain: Any submitted IUCLID file is automatically checked for completeness with an informatics tool called tCC (Technical Completeness Check). The TCC checks whether all mandatory fields are completed. As a consequence, the TCC is successful only if sections 7.8.1 or 7.8.2 of IUCLID are properly filled. They may be void only for intermediates and for substances presented in the lowest tonnage band, i.e. below 10 t/a. Or, it may be that the data were presented but were claimed as confidential. The procedure for asking confidentiality is cumbersome, and the fee paid to ECHA quite expensive, so this opportunity is rarely chosen by submitters. A dossier that fails the TCC can still be presented if suitable justification is provided as free text in IUCLID, but this is not an advisable procedure, as it is followed by extensive controls by ECHA. the number of cases in which the tests are waived is also very high, as it counts 72 and 54 cases, respectively, which represent 17.8% and 13.3% of the total. The waiving option is foreseen when the test is technically not possible for any reasons or it is possible to demonstrate that there is no exposure, so that any risks related to reproductive/developmental toxicity is automatically avoided, as explained in the Column 2 of each Annex (Tab. 1).
Read-across is used in 26.8% and 28% of dossiers, respectively. The basis is Annex XI of the regulation. It is difficult to understand how the very strict criteria (similar in the ECHA guidance) can actually be applied to so many substances in a data-poor area such as reproductive toxicity testing.
limited, and most of the entries must be inserted manually. Even if two dossiers are very similar, the preparation of each can take a very long time. Moreover, each submission is accompanied by a fee that must be paid to ECHA, according to Regulation 340/2008 (Tab. 5). Although this fee seems reasonable, together with the workload necessary for each dossier, the process encourages limiting the total number of submissions. 
Analysis of submitted studies
For all 400 analyzed dossiers, the fields about Reproductive Toxicity (section 7.8.1 in IUCLID) and Developmental Toxicity (section 7.8.2 in IUCLID) were considered. General results are presented in Table 6 . In 18 and 20 cases, the corresponding field was simply not present so it was counted as "void." The reason table 6 is mainly based on data inserted in the key study of each dossier. In order to better understand if this approach was correct, the presence of other studies in the same dossier was considered. Results are reported in Table 7 . The only relevant conclusion is that the contribution of read-across probably is underestimated. It is also clear that testing on a second species is not common in the area of reproductive toxicity but is more frequent in developmental toxicity. Further considerations are not possible, as few data have been collected on additional studies.
Another interesting thought concerns the completeness of the submitted dossiers. Definitive numbers cannot be presented table 6 reports data from the main studies inserted in each dossier, i.e. those that apparently had the highest weight in the final classification. Table 7 further expands these numbers, showing how many of them are associated with other studies for the same purpose. In these tables "QSAR," "Waived," and "Void" are not reported because a dossier is classified as such when no other studies or other contributions were reported. In the analysis, only three in vitro studies were found in the dossiers, but apparently none of them was used as key study for the assessment of the substance. In fact, all the data were published in reviewed journals long before REACH implementation, so clearly the test was not performed for REACH purposes.
The percentage for both waived and void fields is astonishingly high, considering that registered substances should be either HPV or classified as CMRs or environmentally toxic.
As specific rules for adaptation (Tab. 1) include waiving possibilities for carcinogenic and mutagenic substances, the classifications in those areas were checked. Among those waived, six and four carcinogenic substances, respectively, were found; 
Consistency of presented data with CLP requirements
Comparison of presented data with ClP requirements is not straightforward, as CLP requires a classification for toxicity on reproduction and prenatal development combined, and it separates the toxicity via lactation. On the other hand, IUCLID has a section for reproductive toxicity only and another one for developmental toxicity, including both prenatal development and toxicity via lactation. Recorded data are presented in Table 9 . Unfortunately, the IUCLID section, which should explain the reasons for classification, is excluded from the public database, so we could just record the data as they are, with no further discussion possible. However, the uncertainty about the classification is evidenced by the number of "Data Lackhere, because there is no public information as to the registered tonnage band and to the full CSR of the substance. The high numbers for waiving and voids suggest that missing information was not completely addressed. The broad exploitation of the read-across option adds to this. Moreover, the majority of tests proposed in the area of reproductive toxicity are screening studies only. The categorization that was applied is listed in Table 8 . Other applied OECD methods, such as repeated-dose studies, sub-chronic studies, and carcinogenicity studies, were counted as screening methods for the purpose of reproductive toxicity testing. In both fields, the number of studies that are not based on official guidelines is about 40%. Each of these dossiers should be carefully studied to determine whether they are compliant with the requirements. 
New tests performed for REACH purposes and new test proposals
One of the most interesting aspects of the present analysis concerns the type of recent animal studies that have been submitted. what occurred before REACH was published. The situation for the year 2007 is borderline, as it is possible that some tests were planned and initiated the year before, when REACH was still not in place. The effect of REACH can be expected from 2008 onwards, and the increasing trend confirms this assumption (Fig. 2) . It is immediately evident that the number of studies is increasing, starting from 2008. This is easily explained, as planning and performing a new reproductive/developmental toxicity study requires about a year. REACH was published on December 30, 2006. The first SIEFs were formed in 2007, and 2008 is the right time to reap the first results. Of course, the highest number is for 2010, the year of the first deadline. The REACH regulation clearly states that substances that are marketed/manufactured in quantities above 100 t/a require a full reproductive/developmental study, while a simple screening is sufficient when the limit is 10 t/a. Moreover, full studies can be performed only after proper authorization from ECHA, which must first check whether this is really necessary, a process that includes public consultation. Despite this, 10 new OECD TG 416 studies and 14 new OeCD tG 414 studies were performed ing" entries found in the dossiers. For substances that are registered at the highest tonnage band, this is difficult to accept. Analysis of reproductive toxicity can be skipped only when the substance is already classified as carcinogenic. About 10% of the substances that claimed the waiving options for reproductive and developmental toxicity are classified as carcinogenic. The value is higher for voids, as there are five substances that are classified H350, plus three others that indicate only reproductive or developmental toxicity. The only possible explanation is that those substances are marketed in quantities below 10 t/a.
In order to understand better what is happening, each category was further characterized by checking the entries in the corresponding IUCLID section (Tab.10). The data presented for toxicity via lactation can be misleading, as there is a confusion of classification via lactation with the generic developmental toxicity. Table 10 shows discrepancies, as there are many flags for "Data Lacking" while some results are inserted in the corresponding field. On the other hand, the no-classification label is assigned to substances for which the dossier claims the waiving options or the request to perform new in vivo tests. Both cases should be associated with either "Data Lacking" or "Inconclusive." Only few waivings are suggested for substances that have a full RAR and therefore already justify a classification decision. Apparently, the "Inconclusive" option should be selected most often, but the opposite is the case. the OeCD tG 414 is proposed on two species (rat and rabbits), and this was counted twice. It should also be noted that the same study could be inserted twice and used as read-across several times. Additional missing information in our analysis concerns the number of dossiers that have been presented as groupings, which also could increase the numbers presented. table 12 lists the number of animals that are consumed, applying an average number of animals per test as previously evaluated (van der Jagt et al., 2004; Rovida and Hartung, 2009) . Some methods are not focused on reproductive developmental toxicity and are given with a white background. Table 13 addresses costs using the average prices collected by Fleisher (2007) in a survey among the major testing facilities in the EU.
Planned new studies
REACH asks that all new studies, which are very demanding in terms of vertebrate animal use, include open public consultation after 2006. Both numbers are clearly higher than the average performed in the years before, indicating that those studies where probably were performed to comply with REACH. Much more evident is the increase in the number of screening studies (OeCD tG 421 and OeCD tG 422): 47 studies were performed in the years 2008-2010. However, ECHA seems to be aware of those unauthorized tests and probably some actions will be taken (ECHA Report, 2011b) .
this analysis provides input for further assessing the animal consumption for REACH purposes. Assuming that our set of 400 dossiers is representative of the whole array of dossiers submitted so far, table 12 summarizes all tests that presumably were run after 2008, as listed in Table 11 . Reproductive toxicity and developmental toxicity are considered together, as often one test method is inserted in both sections. In those cases, that method is counted once, and this is why the numbers of methods are different from those reported in Table 11 . In only one case, 15) and will cost more than € 60 million (Table 16 ). These numbers are underestimated, as they are based only on open/ closed consultations, but also could be overestimated in some cases, when one study is used for more chemicals in readacross. In our assessment, we that 10.8% and 11.0% of submitted dossiers contain proposals for new tests on reproductive and developmental toxicity (Tab. 6). If those numbers are extrapolated to a total of 4,599 received dossiers, it leads to a total number of 497 new studies for reproductive toxicity and 506 new studies for developmental toxicity. Applying the same calculations to Table 15 , this translates to a total of 396,704 animals for developmental toxicity and 1,590,400 animals for reproductive toxicity, i.e., a total of 1,978,104 animals for just these two endpoints and only for substances registered in the highest tonnage band. these numbers are, on the one hand, somewhat overestimated if the same study can be used several times in grouping (another piece of information that, unfortunately, is not present in the public database) or in read-across. On the other hand, they are underestimated if ECHA decides to ask for a full test when only screening is proposed in a full dossier, when waiving or readacross is not accepted, and for those intermediates that do not fulfill the definition of being an intermediate.
for collecting all possible existing information, with the hope of fulfilling the data needs without performing the test. A section of the ECHA website 7 lists all these consultations under the title "Proposals for tests involving vertebrate animals." As expected (Rovida and Hartung, 2009) , the vast majority of planned studies concern reproductive and developmental toxicity. Of a total number of open consultations for 192 new substances (on 10 September, 2011), 93 suggest further assessment of reproductive toxicity and 120 of (pre)natal developmental, i.e. 48% and 62.5%, respectively.
Planned studies in public consultation usually are published without specifying the guideline that is going to be applied 8 (Tab. 14). The aim is to open the doors to as many opportunities as possible. Thus far, however, only four dossiers have reached the end of the process, with the authorization of all proposed tests, including reproductive toxicity and developmental toxicity. The hope that other dossiers will have a better outcome is not very high. Again, the opportunity for more advanced testing strategies with the application of in vitro methods was not considered.
Assuming that reproductive toxicity will require OECD TG 416 and (pre)natal developmental toxicity OECD TG 414, planned studies will use half a million animals or more (Tab. 
Projection from the 400 analyzed dossiers to all 4,599 dossiers
This sample of 400 dossiers allows us to project costs of the first phase of REACH. If all 4,599 dossiers were to lead to testing for reproductive and developmental toxicity, € 1.3 billion and 13 million animals would be required. Reducing the number of intermediates (which do not require testing), the costs come down to € 0.9 billion and 9.2 million animals. If all dossiers where submitters state "conclusive data lacking" (18%) resulted in testing, € 234 million and 1.3 million animals would be needed.
In contrast, submitters propose studies at costs of € 70 million and almost 700,000 animals (Tab. 15, 16). It is worth noting that the number of studies already carried out after 2007 is even higher, i.e. costing € 140 million and using almost 900,000 animals (Tab. 12, 13). Taken together, this first phase of REACH consumes about € 240 million and uses almost 1.6 million animals for reproductive and developmental toxicity only (assumed to represent 90% of the total). However, it is likely that not all data will be accepted as submitted: Existing in vivo data will not always be acceptable, and whether waiving, read-across, and alternative techniques will be accepted by regulators, as suggested by industry, is not clear at all. A further increase in both numbers is likely.
Comparison with previous estimation
The number of substances for phase one of REACH is higher than expected (3,599 compared to the 2,700 originally expected by the European Commission). Numbers are not as high as our model calculation from 2009 (Rovida and Hartung, 2009 ) suggested, most likely because we do not have a linear spread of production volumes (especially for the high production volume (HPV) chemicals currently registered). Also, including several substances in one dossier might contribute to apparently lower numbers. As shown earlier (Hartung and Rovida, 2009b) , all previous estimates were based on a single database from 1991-1994; we corrected for the increase from 12 to 27 member states, A minor hope came from the last meeting of the Member State Committee at ECHA, where the request for a new twogeneration study for five substances could not find unanimous agreement. The application of OECD test guideline 443 for the extended one-generation reproductive toxicity study was proposed as an alternative (ECHA News Alert, 2011).
In vitro opportunities
the complete absence of in vitro approaches is difficult to accept, even though already predicted (Rovida, 2010) . However, this is largely due to the ECHA guideline, which states that no in vitro method can be applied for REACH purposes in the fields of reproductive and developmental toxicity. The situation is even worse: the guideline describes in vitro methods as an opportunity to trigger further in vivo testing. The only real possibility for in vitro testing lies in justifying a read-across approach. Unfortunately, the considerable limitations of in vivo methods -with a predictivity known to be around 60% only (Hartung, 2009) (Adler et al., 2011) : "Only animal models are hitherto accepted as adequately representing the complexity and providing an assessment of the complex interaction of chemicals on the reproductive system." On the other hand, the European Commission recently funded the 5-year Integrated Project ReProTect to develop new in vitro tests to replace animal experimentation in reproductive toxicology 10 with € 9.1 million. The outcome from this project was very successful, with a proposal for a battery of tests that may replace in vivo methods in the near future (Schenk et al., 2010) . Results from ReProTect are to be combined with other research projects 11,12 , demonstrating a lively and rapidly progressing arena. For example, preliminary experiments demonstrated that there were no false negative substance classifications in the feasibility study, making the ReProTect battery of tests suitable for screening or at least to confirm negative results from in vivo screening tests.
therefore, even though full replacement is not available at the moment, some in vitro tests could complement the information derived from a screening test or confirm the result from an existing test that lacks information to be accepted as fully 9 http://tsar.jrc.ec.europa.eu 10 www.ReProTect.eu 11 www.esnats.eu 12 www.scrtox.eu of the large majority of dossiers -those that propose avoiding testing -will not work. This penalizes those who followed the guidance and suggested tests.
If only the proposed studies are done (about 219 developmental and 159 reproductive toxicity studies, when extrapolating to the entire number of dossiers, for phase one of REACH), the numbers will already exceed current European test capacities. Fleischer (2007) identified test capacities for 12 developmental studies in rabbits and 28 reproductive studies in rats per year in Europe (mainly used for pesticides and drugs). It is very unlikely that there is much more capacity and that all this could be handled in a few years. Test capacities cannot be easily created, as they require complex knowledge and experience (GLP, histopathology, etc.) . This is the number used so far for chemical testing over the past 10 years. And this is only the first part of the program.
The use of alternatives so far is negligible. We need to use the momentum to foster alternative approaches, especially in reproductive toxicity testing. The first step forward would be the change from a two-generation to a one-generation study, which would reduce animal use and costs by more than 60%. Unfortunately, although the OeCD accepted this test, it has not yet been adopted for REACH (Gilbert, 2010) . Another important opportunity would be the applicability of methods developed by ReProTect for confirming both positive and negative results. In our opinion, this would also dramatically enhance the knowledge about the chemicals' activity on human health, which is exactly in the spirit of REACH.
The purpose of REACH is to get much data on many chemicals. For the HPV chemicals, if only 11% of new tests are carried out, the information gained will be limited. But the feasibility of even this minimal program is questionable. At the same time, it is understandable that industry wants to avoid costly testing, especially since precautionary test methods will lead to many false allegations for toxic properties (Hartung, 2009) . The dilemma can only be solved if it creates momentum for new approaches, but there is little indication that this is happening.
A legislative amendment of REACH is foreseen for 2012. We strongly advocate that the explicit requirements for OECD TG 414 and 416 disappear and applicability of (pre-)validated in vitro methods within the scope of Annex XI include the possibility of accepting both positive and negative results, if backed by satisfactory scientific evidence. It is worth remembering that none of the in vivo methods for testing reproductive and developmental toxicity has ever been validated.
Another important consideration concerns the strong differences between some registration dossiers: It seems unfair that diligent submitters admitted that their dossiers were lacking important information and asked for the permission to perform new tests, while others simply did the test without permissions or used data of limited scientific relevance to fill the box. At this point the better approach would be to halt the authorization for new in vivo tests and develop a more integrated strategy that takes advantage of in silico and in vitro approaches. This possibility may provide evidence to weigh whether the assessed substance is likely to be dangerous and requires extensive in plus others applying REACH and, on average, a 5% increase in production volume per year.
The first surprise was that there is more existing data on developmental and reproductive toxicity available than expected (39.5% and 42.3%, respectively) instead of the 7% as estimated by the former European Chemicals Bureau, (Pedersen et al., 2003) , but in line with earlier statements by industry. This is not what we see in the database of the US EPA for 2,000 HPV substances, where very little test information for reproductive toxicity is available (Bremer et al., 2007) . Thus it appears that studies of lesser relevance have now been brought forward, but this cannot be confirmed at this stage. Furthermore, there is a clear indication that some studies were done just before registration, which is clearly illegal, as they would have required acceptance of the testing proposal after public consultation by ECHA. The extrapolation to all dossiers (Tab. 12, 13) shows that we are talking about an impressive number of studies, which used about 900,000 animals and cost € 140 million.
the very rigid guidance for testing is not followed by industry. Waiving is quite broadly applied (17.8% for developmental and 13.3% for reproductive toxicity studies, plus 4.5% and 5%, respectively, of voids), though the current guidance is extremely strict. Only 10.8% and 11% of dossiers proposed animal studies, while at least 47% of developmental and 18% of reproductive toxicity data are either lacking or inconclusive. This shows that roles are changing here: ECHA needs not to limit the testing, but to request it. This means that a pure completeness check of 5% of dossiers not suggesting tests will not suffice to attain the goals of REACH.
In vitro and in silico approaches play no role, an observation very much in line with our previous comments (Rovida, 2010) . The limited use of (Q)SAR reflects the lack of predictive models as stated recently (Hewitt et al., 2010) : "This study has shown that current modelling methods available for developmental toxicity are still in their infancy. Each approach considered in this study is limited by available toxicity data in the public arena and by mechanistic understanding." Some in vitro methodologies are available (Seiler and Spielmann, 2011; Marx-Stoelting et al., 2009; Schenk et al., 2010; West et al., 2010) , but few are validated (Genschow et al., 2004) and none accepted for regulatory use or recommended in the guidance. REACH would, however, be open to their use on a weight of evidence basis. The fact that companies do not use this option reflects the general impression as to their limited acceptance (if at all for positive findings) and the possible triggering of even more extensive (animal) testing.
Conclusions
REACH is at a critical crossroads. The position the agency now takes toward the few test proposals received, the acceptability of existing data, waiving, and read-across will be very important. Revision of intermediates also deserves attention. As many animal tests as possible should be avoided, but they must be the right ones to avoid. Checking the completeness of only 5% vivo reproductive toxicity testing. In the meanwhile, a general control of all dossiers could take place. Only when this analysis is completed, a more modern approach can be implemented and used to fill the many gaps that are evident at this stage of the process.
